GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

49.55 0.53 +1.08%
Market cap
$98.2B
P/E
15.4×
Fwd P/E
12.4×
Dividend yield
3.67%
F-score
9/9
Altman Z
2.12
Beneish M
−2.46
Dividend safety
54/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
30.74% 38.52% 39.92% 37.41%

+8 more TTM periods

Piotroski F-Score
8 8 9 8
ROA
8.01% 9.72% 9.63% 9.16%
ROIC
12.58% 15.14% 16.44% 15.28%
Return on Tangible Assets
89.82% 124.42% 105.05% 91.88%
Average Days of Receivables
88.86 88.94 86.69 97.18
Free Cash Flow per Share
3.81 3.25 3.19 3.19
Free Cash Flow
7,647.98 6,540.67 6,455.04 6,440.71
Capital Expenditures
(3,372.99) (3,762.76) (3,753.02) (3,803.19)
Other line items
Cash ROIC
14.76% 12.13% 13.16% 12.94%
Accounts Receivable Turnover
4.22 4.36 4.40 3.92
Accounts Payable Turnover
0.62 0.62 0.60 0.58
Inventory Turnover
1.47 1.51 1.58 1.46
Average Days of Payables
579.33 588.64 622.61 662.34
Days of Inventory on Hand
253.75 252.83 239.80 258.51
Tax Rate
(0.11) (0.15) (0.15) (0.14)
Research and Development Expense of Revenue
27.66% 23.61% 23.04% 22.41%
Selling, General and Administrative Expense of Revenue
27.70% 27.87% 27.82% 28.21%
Share Based Compensation of Revenue
0.00% 0.00% 4.05% 0.00%
Interest Coverage
9.22 11.38 11.32 11.05
Operating CF/Net income
1.70 1.32 1.35 1.41
Depreciation/Fixed assets
0.33 0.21 0.25 0.33
Capex/Depreciation
(0.82) (1.43) (1.23) (0.92)
Revenue per Share
22.18 21.82 21.27 20.84
Operating CF per Share
5.49 5.12 5.04 5.08
Capex per Share
(1.68) (1.87) (1.85) (1.89)
Capex to Sales
0.08 0.09 0.09 0.09

Fold the line items

Columns are period end dates